Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Current Deferred Revenue (2022 - 2025)

AVITA Medical's Current Deferred Revenue history spans 4 years, with the latest figure at $323000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 9.52% year-over-year to $323000.0; the TTM value through Dec 2025 reached $323000.0, down 9.52%, while the annual FY2025 figure was $323000.0, 9.52% down from the prior year.
  • Current Deferred Revenue reached $323000.0 in Q4 2025 per RCEL's latest filing, down from $331000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $698000.0 in Q4 2022 to a low of $205000.0 in Q2 2024.
  • Average Current Deferred Revenue over 4 years is $414000.0, with a median of $365000.0 recorded in 2024.
  • Peak YoY movement for Current Deferred Revenue: plummeted 63.2% in 2024, then skyrocketed 65.85% in 2025.
  • A 4-year view of Current Deferred Revenue shows it stood at $698000.0 in 2022, then tumbled by 44.13% to $390000.0 in 2023, then fell by 8.46% to $357000.0 in 2024, then decreased by 9.52% to $323000.0 in 2025.
  • Per Business Quant, the three most recent readings for RCEL's Current Deferred Revenue are $323000.0 (Q4 2025), $331000.0 (Q3 2025), and $340000.0 (Q2 2025).